鹽酸納美芬聯合曲克蘆丁腦蛋白水解物注射液治療新生兒缺氧缺血性腦病的臨床效果

龔梨林

【摘要】 目的：探討鹽酸納美芬聯合曲克蘆丁腦蛋白水解物注射液治療新生兒缺氧缺血性腦病的臨床效果。方法：選取2012年10月-2015年11月本院確診治療的缺氧缺血性腦病患兒100例，依據隨機分配原則分為美芬蛋白組和美芬組，每組50例。美芬組患兒給予常規基礎治療及鹽酸納美芬治療，美芬蛋白組患兒在此基礎上給予曲克蘆丁腦蛋白水解物注射液治療，采用神經行為測定（NBNA）評分評估患兒的神經功能，采用Gesell發育量表評估患兒智能發育情況，并統計分析患兒的臨床療效和不良反應發生情況。結果：美芬蛋白組患兒治療總有效率、NBNA評分及DQ均明顯高于美芬組，差異均有統計學意義（P<0.05）；美芬蛋白組和美芬組患兒不良反應發生率分別為16.00%、6.00%，兩組比較差異無統計學意義（P>0.05）。結論：鹽酸納美芬聯合曲克蘆丁腦蛋白水解物注射液治療可有效緩解新生兒缺氧缺血性腦病的臨床癥狀，提高患兒的臨床療效，且具有良好的安全性，值得臨床作進一步推廣。

【關鍵詞】 新生兒； 缺氧缺血性腦病； 鹽酸納美芬； 曲克蘆丁腦蛋白水解物注射液

【Abstract】 Objective：To explore the clinical efficacy of Nalmefene Hydrochloride combined with Troxerutin and Cerebroprotein Hydrolysate Injection in treatment of newborn hypoxic ischemic encephalopathy.Method：100 children with hypoxic ischemic encephalopathy in our hospital from October 2012 to November 2015 were selected，they were randomly divided into Mefene-protein group and Mefene group，50 cases in each group.The Mefene group was given conventional treatment and Nalmefene Hydrochloride treatment，while the Mefene-protein group was additionally given Cerebroprotein Hydrolysate Injection treatment.Neonatal behavioral neurological assessment（NBNA） score was used to assess the neurological function，and the Gesell development scale was used to assess the intelligence development of the children，the clinical efficacy and adverse reactions of the patients were statistically analyzed.Result：The total effective rate，NBNA score and DQ of Mefene-protein group were significantly higher than those in Mefene group（P<0.05）.The incidence of adverse reactions was 16.00% in the Mefene-protein group and 6.00% in the Mefene group，the difference was no statistically significant（P>0.05）.Conclusion：Nalmefene Hydrochloride combined with Troxerutin and Cerebroprotein Hydrolysate Injection can effectively alleviate the clinical symptoms of neonatal hypoxic ischemic encephalopathy，improve the clinical efficacy of children，and has a good safety，it is worth of further promotion.

【Key words】 Newborn； Hypoxic ischemic encephalopathy； Nalmefene Hydrochloride； Troxerutin and Cerebroprotein Hydrolysate Injection

First-authors address：Fengcheng Peoples Hospital，Fengcheng 331100，China

doi：10.3969/j.issn.1674-4985.2016.36.028

新生兒缺氧缺血性腦病是臨床上新生兒常見的一種臨床高危病癥，是圍生期新生兒因缺氧引起腦部病變所致，可導致意識模糊、驚厥、呼吸節律不齊等癥狀，嚴重影響患兒的身體健康[1]。目前，新生兒缺氧缺血性腦病臨床上多采用吸氧、保暖、降顱內壓、止驚等基礎治療[2-4]，可有效緩解患兒的臨床癥狀，但由于新生兒體質虛弱，導致療效欠佳，故如何提高患兒的臨床療效成為了廣大學者重點關注的問題。對此，本研究通過給予患兒鹽酸納美芬聯合曲克蘆丁腦蛋白水解物注射液治療，探討其對患兒的療效的影響及其安全性，現報道如下。

1 資料與方法endprint